{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T18:42:03Z","timestamp":1772390523930,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T00:00:00Z","timestamp":1564531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T00:00:00Z","timestamp":1564531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1137034"],"award-info":[{"award-number":["OPP1137034"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1137034"],"award-info":[{"award-number":["OPP1137034"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1137034"],"award-info":[{"award-number":["OPP1137034"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1137034"],"award-info":[{"award-number":["OPP1137034"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1137034"],"award-info":[{"award-number":["OPP1137034"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Achieving the WHO End-Tuberculosis (TB) targets requires approaches to prevent progression to TB among individuals with <jats:italic>Mycobacterium tuberculosis (M.tb)<\/jats:italic> infection. Effective preventive therapy (PT) exists, but current tests have low specificity for identifying who, among those infected, is at risk of developing TB. Using mathematical models, we assessed the potential population-level impact on TB incidence of using a new more specific mRNA expression signature (COR) to target PT among HIV-uninfected adults in South Africa. We compared the results to the use of the existing interferon-\u03b3 release assay (IGRA). With annual screening coverage of 30% COR-targeted PT could reduce TB incidence in 2035 by 20% (95% CI 15\u201327). With the same coverage, IGRA-targeted PT could reduce TB incidence by 39% (31\u201348) but would require greater use of PT resulting in a higher number needed to treat per TB case averted (COR: 49 (29\u201377); IGRA: 84 (59\u2013123)). The relative differences between COR and IGRA were not sensitive to screening coverage. COR-targeted PT could contribute to reducing total TB burden in high incidence countries like South Africa by allowing more efficient targeting of treatment. To maximise impact, COR-like tests may be best utilised in the highest burden regions, or sub-populations, within these countries.<\/jats:p>","DOI":"10.1038\/s41598-019-47645-z","type":"journal-article","created":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T10:02:57Z","timestamp":1564567377000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Potential population level impact on tuberculosis incidence of using an mRNA expression signature correlate-of-risk test to target tuberculosis preventive therapy"],"prefix":"10.1038","volume":"9","author":[{"given":"Tom","family":"Sumner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0641-1359","authenticated-orcid":false,"given":"Thomas J.","family":"Scriba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Penn-Nicholson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Hatherill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4410-6635","authenticated-orcid":false,"given":"Richard G.","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,31]]},"reference":[{"key":"47645_CR1","unstructured":"World Health Organisation. The End TB Strategy. Geneva, Switzerland: World Health Organisation (2015)."},{"key":"47645_CR2","doi-asserted-by":"publisher","unstructured":"Dye, C, Glaziou, P., Floyd, K. & Raviglione, M. Prospects for tuberculosis elimination. Annu Rev Public Health. 34, 271\u201386. Epub 2012\/12\/19. PubMed PMID: 23244049, https:\/\/doi.org\/10.1146\/annurev-publhealth-031912-114431 (2013).","DOI":"10.1146\/annurev-publhealth-031912-114431"},{"key":"47645_CR3","unstructured":"Smieja, M. J., Marchetti, C. A., Cook, D. J. & Smaill, F. M. Isoniazid for preventing tuberculosis in non-HIV infected persons (Review). The Cochrane Library. 2 (2005)."},{"key":"47645_CR4","doi-asserted-by":"crossref","unstructured":"Sterling, T. et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. NEJM. 365(23) (2011).","DOI":"10.1056\/NEJMoa1104875"},{"key":"47645_CR5","doi-asserted-by":"publisher","unstructured":"Houben, R. M. & Dodd, P. J. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. PLoS Med. 13(10), e1002152, https:\/\/doi.org\/10.1371\/journal.pmed.1002152. PubMed PMID: 27780211, PubMed Central PMCID: PMC5079585 (2016).","DOI":"10.1371\/journal.pmed.1002152."},{"key":"47645_CR6","doi-asserted-by":"publisher","unstructured":"Petruccioli, E et al. Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis. Eur Respir J. 48(6), 1751\u201363, https:\/\/doi.org\/10.1183\/13993003.01012-2016. PubMed PMID: 27836953 (2016).","DOI":"10.1183\/13993003.01012-2016."},{"key":"47645_CR7","doi-asserted-by":"publisher","unstructured":"Suliman, S. et al. Four-gene Pan-African Blood Signature Predicts Progression to Tuberculosis. Am J Respir Crit Care Med., https:\/\/doi.org\/10.1164\/rccm.201711-2340OC PubMed PMID: 29624071 (2018).","DOI":"10.1164\/rccm.201711-2340OC"},{"key":"47645_CR8","unstructured":"World Health Organisation. Consensus meeting report: development of a Target Product Profile (TPP) and a framework for evaluation for a test for predicting progression from tuberculosis infection to active disease. Geneva, Switzerland (2017)."},{"key":"47645_CR9","doi-asserted-by":"publisher","unstructured":"Zak, D. E. et al. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet. 387(10035), 2312\u201322. PubMed PMID: 27017310, PubMed Central PMCID: PMC5392204, https:\/\/doi.org\/10.1016\/S0140-6736(15)01316-1 (2016).","DOI":"10.1016\/S0140-6736(15)01316-1"},{"key":"47645_CR10","doi-asserted-by":"publisher","unstructured":"Darboe, F. et al. Diagnostic performance of an optimized transcriptomic signature of risk of tuberculosis in cryopreserved peripheral blood mononuclear cells. Tuberculosis. 108, 124\u20136, https:\/\/doi.org\/10.1016\/j.tube.2017.11.001. PubMed PMID: 29523312 (2018).","DOI":"10.1016\/j.tube.2017.11.001."},{"key":"47645_CR11","doi-asserted-by":"publisher","unstructured":"Fiore-Gartland, A et al. Considerations for biomarker-targeted intervention strategies for TB prevention. Tuberculosis. In press, https:\/\/doi.org\/10.1016\/j.tube.2017.11.009 (2017).","DOI":"10.1016\/j.tube.2017.11.009"},{"key":"47645_CR12","unstructured":"World Health Organisation. Global Tuberculosis Report Geneva2018 Available from, https:\/\/www.who.int\/tb\/publications\/global_report\/en\/ [cited 2018 20th September]."},{"key":"47645_CR13","unstructured":"Statistics South Africa. Mortality and causes of death in South Africa: Findings from death notification, Pretoria: Statistics South Africa, 2018 [cited 2018 3rd April]. Available from, http:\/\/www.statssa.gov.za\/?page_id=1854&PPN=P0309.3&SCH=7308 (2016)."},{"key":"47645_CR14","unstructured":"World Health Organisation. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva, Switzerland (2011)."},{"key":"47645_CR15","unstructured":"Department of Health South Africa, South African National AIDS Council. South Africa\u2019s National Strategic Plan for HIV, TB and STIs 2017\u20132022 Pretoria, South Africa2017 Available from, http:\/\/sanac.org.za\/wp-content\/uploads\/2017\/05\/NSP_FullDocument_FINAL.pdf [cited 2017 15th September]."},{"key":"47645_CR16","unstructured":"World Health Organisation. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva (2018)."},{"key":"47645_CR17","doi-asserted-by":"publisher","unstructured":"Houben, R. M. et al. TIME Impact - a new user-friendly tuberculosis (TB) model to inform TB policy decisions. BMC Med. 14, PubMed PMID: 27012808, PubMed Central PMCID: PMC4806495, https:\/\/doi.org\/10.1186\/s12916-016-0608-4 (2016).","DOI":"10.1186\/s12916-016-0608-4"},{"key":"47645_CR18","doi-asserted-by":"publisher","unstructured":"Menzies, N. A., Cohen, T., Lin, H. H., Murray, M & Salomon, J. A. Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB\/RIF: a dynamic simulation and economic evaluation. PLoS Med. 9(11), e1001347. Epub 2012\/11\/28 PubMed PMID: 23185139, PubMed Central PMCID: PMC3502465, https:\/\/doi.org\/10.1371\/journal.pmed.1001347 (2012).","DOI":"10.1371\/journal.pmed.1001347"},{"key":"47645_CR19","doi-asserted-by":"publisher","unstructured":"Johnson, J. L. et al. Effect of isoniazid therapy for latent TB infection on QuantiFERON-TB gold in-tube responses in adults with positive tuberculin skin test results in a high TB incidence area: a controlled study. Chest. 145(3), 612\u20137 PubMed PMID: 24135768, PubMed Central PMCID: PMC3941252, https:\/\/doi.org\/10.1378\/chest.13-1232 (2014).","DOI":"10.1378\/chest.13-1232"},{"key":"47645_CR20","doi-asserted-by":"publisher","unstructured":"Arinaminpathy, N. & Dowdy, D. Understanding the incremental value of novel diagnostic tests for tuberculosis. Nature. 528(7580), S60\u20137 PubMed PMID: 26633767, https:\/\/doi.org\/10.1038\/nature16045 (2015).","DOI":"10.1038\/nature16045"},{"key":"47645_CR21","unstructured":"World Health Organisation. WHO TB Burden Estimates Geneva2016 Available from, https:\/\/extranet.who.int\/tme\/generateCSV.asp?ds=estimates [cited 2017 17th September]."},{"key":"47645_CR22","unstructured":"HIV estimates with uncertianty bounds 1990\u20132016 [Internet]. Available from, http:\/\/www.unaids.org\/en\/resources\/documents\/2017\/HIV_estimates_with_uncertainty_bounds_1990-2016 (2016)."},{"key":"47645_CR23","doi-asserted-by":"publisher","unstructured":"Houben, R. M., Sumner, T., Grant, A. D. & White, R. G. Ability of preventive therapy to cure latent Mycobacterium tuberculosis infection in HIV-infected individuals in high-burden settings. Proc Natl Acad Sci USA 111(14), 5325\u201330. PubMed PMID: 24706842, PubMed Central PMCID: PMC3986199, https:\/\/doi.org\/10.1073\/pnas.1317660111 (2014).","DOI":"10.1073\/pnas.1317660111"},{"key":"47645_CR24","doi-asserted-by":"crossref","unstructured":"Sumner, T. et al. Post-Treatment Effect of Isoniazid Preventive Therapy on Tuberculosis Incidence in Hiv-Infected Individuals on Antiretroviral Therapy. AIDS. ePub (2016).","DOI":"10.1097\/QAD.0000000000001078"},{"key":"47645_CR25","doi-asserted-by":"crossref","unstructured":"Churchyard, G., Chaisson, R. E., Maartens, G. & Getahun, H. Tuberculosis preventive therapy: an underutilised strategy to reduce individual risk of TB and contribute to TB control. S Afr Med J. 104 (2014).","DOI":"10.7196\/SAMJ.8290"},{"key":"47645_CR26","doi-asserted-by":"publisher","unstructured":"Balcells, M. E., Thomas, S. L., Godfrey-Faussett, P. & Grant, A. D. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis. 12(5), 744\u201351. PubMed PMID: 16704830, PubMed Central PMCID: PMC3374455, https:\/\/doi.org\/10.3201\/eid1205.050681 (2006).","DOI":"10.3201\/eid1205.050681"},{"key":"47645_CR27","doi-asserted-by":"publisher","unstructured":"Mills, H. L., Cohen, T. & Colijn, C. Community-wide isoniazid preventive therapy drives drug-resistant tuberculosis: a model-based analysis. Sci Transl Med. 5(180), 180ra49. PubMed PMID: 23576815, PubMed Central PMCID: PMC3714172, https:\/\/doi.org\/10.1126\/scitranslmed.3005260 (2013).","DOI":"10.1126\/scitranslmed.3005260"},{"key":"47645_CR28","doi-asserted-by":"publisher","unstructured":"Johnson, J. L. et al. Effect of Isoniazid Therapy for Latent TB Infection on QuantiFERON-TB Gold In-Tube Responses in Adults With Positive Tuberculin Skin Test Results in a High TB Incidence Area. Chest. 145(3), 612\u20137. PubMed PMID: 27845635, https:\/\/doi.org\/10.1378\/chest.13-1232 (2014).","DOI":"10.1378\/chest.13-1232"},{"key":"47645_CR29","doi-asserted-by":"publisher","unstructured":"Lee, S. W., Lee, S. H. & Yim, J. J. Serial interferon-gamma release assays after chemoprophylaxis in a tuberculosis outbreak cohort. Infection. 40(4), 431\u20135. PubMed PMID: 22585454, https:\/\/doi.org\/10.1007\/s15010-012-0265-2 (2012).","DOI":"10.1007\/s15010-012-0265-2"},{"key":"47645_CR30","doi-asserted-by":"publisher","unstructured":"Metcalfe, J. Z. et al. Interferon-gamma release assays for active pulmonary tuberculosis diagnosis in adults in low- and middle-income countries: systematic review and meta-analysis. J Infect Dis. 204, Suppl 4, S1120\u20139 PubMed PMID: 21996694, PubMed Central PMCID: PMC3192542, https:\/\/doi.org\/10.1093\/infdis\/jir410 (2011).","DOI":"10.1093\/infdis\/jir410"},{"key":"47645_CR31","doi-asserted-by":"publisher","unstructured":"Penn-Nicholson, A., Scriba, T. J., Hatherill, M., White, R. G. & Sumner, T. A novel blood test for tuberculosis prevention and treatment. S Afr Med J. 107(1), 4\u20135 PubMed PMID: 28112082, https:\/\/doi.org\/10.7196\/SAMJ.2016.v107.i1.12230 (2016).","DOI":"10.7196\/SAMJ.2016.v107.i1.12230"},{"key":"47645_CR32","doi-asserted-by":"publisher","unstructured":"Rangaka, M. X. et al. Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 12(1), 45\u201355 PubMed PMID: 21846592, PubMed Central PMCID: PMC3568693, https:\/\/doi.org\/10.1016\/S1473-3099(11)70210-9 (2012).","DOI":"10.1016\/S1473-3099(11)70210-9"},{"key":"47645_CR33","doi-asserted-by":"crossref","unstructured":"Pai, M., Zwerling, A. & Menzies, D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med. 149(3) (2008).","DOI":"10.7326\/0003-4819-149-3-200808050-00241"},{"key":"47645_CR34","doi-asserted-by":"publisher","unstructured":"Steingart, K. R. et al. Xpert(R) MTB\/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 1, CD009593. Epub 2013\/02\/27. PubMed PMID: 23440842, https:\/\/doi.org\/10.1002\/14651858.CD009593.pub2 (2013).","DOI":"10.1002\/14651858.CD009593.pub2"},{"key":"47645_CR35","doi-asserted-by":"publisher","unstructured":"Sandgren, A. et al. Initiation and completion rates for latent tuberculosis infection treatment: a systematic review. BMC Infect Dis. 16, 204 PubMed PMID: 27184748, PubMed Central PMCID: PMC4869320, https:\/\/doi.org\/10.1186\/s12879-016-1550-y (2016).","DOI":"10.1186\/s12879-016-1550-y"},{"key":"47645_CR36","unstructured":"Belgorodski, N., Greiner, M., Tolksdorf, K. & Katharina, S. Rrisk distributions: Fitting Distributions to Given Data or Known Quantiles (2017)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-47645-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-47645-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-47645-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T12:09:40Z","timestamp":1671278980000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-47645-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,31]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["47645"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-47645-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,31]]},"assertion":[{"value":"10 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"11126"}}